Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP1009 | DOI: 10.1530/endoabs.49.EP1009

1Coimbra Hospital and University Center, Coimbra, Portugal; 2Faculty of Medicine University of Coimbra, Coimbra, Portugal.


Background: Pituitary adenomas (PA) are common intracranial tumors that are mainly considered benign. A small group of patients exhibit clinically aggressive behavior sometimes unrelated to the histopathological or radiological features.

Methods: Twelve patients were selected harboring a PA with clinical features of aggressiveness. All the patients underwent pre and postoperative endocrinologic/neuroradiologic evaluation.

Results: 10/12 patients were male, mean age at diagnosis 38.1 years (range 12–58) and mean follow-up 14.3 years (range 5–28; died 3/12). In 9/12 cases, the first manifestation was visual impairment (visual field loss, reduction in visual acuity and/or cranial nerve palsies). All the patients had invasive pituitary macroadenomas with expansion into surrounding anatomical structures (11 cavernous sinus; 7 sphenoid sinus; 7 bone invasion). The 12 patients underwent a total of 52 surgical procedures (median 4; range 3–6). Apparently total removal was achieved in 8/12 patients at the first surgical procedure. Regarding histological subtype: 5 gonadotrophinomas; 2 null-cell adenomas; 2 corticotrophinomas; 1 thyrotrophinoma; 1 prolactinoma and 1 plurihormonal adenoma (GH/ACTH). Proliferation markers as ki67 >3% was identified in 4; >2mitoses/10 HPF in 3 and p53 IHC expression in 4/12 cases. Six patients underwent radiation therapy (RT) postoperatively (5 conventional external RT; 1 stereotactic radiosurgery). Medical therapy was tried in 4/12 patients: 3 with dopamine agonists; 1 with somatostatin analog (pasireotide); 2 with steroidogenesis inhibitors (ketoconazole and metyrapone). Possible metastatic pulmonary disease was identified only in one case; the patient died of tumor progression 10-years after the diagnosis.

Conclusion: Aggressive pituitary tumors constitute a challenging but not completely defined entity. We found an elevated number of surgical procedures by patient and smaller proportion of RT/medical treated patients compared with literature, however, with similar outcomes. Adverse results in treatment are possibly related to difficulty in early detection of this patients’ subgroup that must be treated with a multimodal approach.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts